SAB Biotherapeutics is trading at $3.35, up 5.35%, amid a positive biotech-sector backdrop; no company-specific announcement has been confirmed. - Market context reports biotech ETF strength in pre-market. - Q3 2026 results are scheduled for November 5, with a conference call at 8:30 a.m. ET. - No results were available in the information reviewed by 5:42 a.m. ET. Earnings-release timing may also have investors’ attention, but does not establish the cause of the move.